BTMD

biote Corp.

biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements. It also sells Biote-branded dietary supplements; and sterile pellet insertion kits for men and women. The company was founded in 2011 and is headquartered in Irvine, Texas.

biote Corp. (BTMD) is rated C+ (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B); its weakest is Momentum (D+).

Quantitative Factor Evaluation • Updated

Overall Rating
2.5 / 5.0
C+
Value
B
Factor Score 3.2 / 5.0
Growth
C
Factor Score 2.3 / 5.0
Profitability
C+
Factor Score 2.8 / 5.0
Momentum
D+
Factor Score 1.7 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 2.8
EV / EBITDA 12.4
Rev Growth YoY -9.6%
Gross Margin 67.5%
Price Return 3M -26.1%
Price Return 12M -63.1%
Catalyst Signal 0.00
Market Cap $31.0M
TTM Revenue $178.9M
Price / Sales 0.2
ROE N/A

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 B (3.2) C (2.3) C+ (2.8) D+ (1.7) C+ (2.6) C+ (2.5)
2026-11-10 B (3.4) C (2.2) C+ (2.8) D+ (1.6) C+ (2.6) C+ (2.5)
2026-11-03 B (3.3) C- (2.1) B- (2.9) D- (1.0) C+ (2.7) C (2.4)
2026-10-27 B (3.3) C- (2.1) B- (2.9) D- (1.0) C+ (2.6) C (2.4)
2026-10-20 B (3.3) C- (2.1) B- (2.9) D- (1.0) C+ (2.6) C (2.4)
Page 1 of 4